2007
DOI: 10.4103/0019-509x.35813
|View full text |Cite
|
Sign up to set email alerts
|

Role of chelates in treatment of cancer

Abstract: Chelates are used in cancer as cytotoxic agent, as radioactive agent in imaging studies and in radioimmunotherapy.Various chelates based on ruthenium, copper, zinc, organocobalt, gold, platinum, palladium, cobalt, nickel and iron are reported as cytotoxic agent. Monoclonal antibodies labeled with radioactive metals such as yttrium-90, indium-111 and iodine-131 are used in radioimmunotherapy. This review is an attempt to compile the use of chelates as cytotoxic drugs and in radioimmunotherapy.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
21
0

Year Published

2010
2010
2020
2020

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 44 publications
(22 citation statements)
references
References 47 publications
1
21
0
Order By: Relevance
“…Copper(II) complexes are supposed to act by triggering cell apoptosis or inhibiting enzymes (Tripathi et al, 2007). In fact, the expression of tyrosine-protein kinase CSK is inhibited by complexes of Cu(II) with pyridine-2-carbohidrazide derivatives.…”
Section: Coppermentioning
confidence: 99%
“…Copper(II) complexes are supposed to act by triggering cell apoptosis or inhibiting enzymes (Tripathi et al, 2007). In fact, the expression of tyrosine-protein kinase CSK is inhibited by complexes of Cu(II) with pyridine-2-carbohidrazide derivatives.…”
Section: Coppermentioning
confidence: 99%
“…[10] Palladium amine complexes have also been investigated for their potential use as anticancer agents [11] and some Palladium(II) complexes of Schiff base ligands have been found to exhibit marked cytotoxicity against leukemia. [12] For a number of years, Platinum-based chemotherapeutic regimens have been the mainstay for the management of epithelial ovarian cancer, [13] testicular cancer, head and neck tumors, and a number of other solid tumor types. [14] The platinum analogue oxaliplatin has been developed and is now licensed for use in matastatic colon cancer in the U.S. [15] The accessibility of ruthenium in higher oxidation states [16,17] converts the transition metal complexes into excellent species that act as catalyst for redox reactions.…”
Section: Introductionmentioning
confidence: 99%
“…Therefore, the structure of nicotinamide has been the subject of many studies [58]. Uses of metal ions in therapeutic agents are known to accelerate drug action and their efficacy enhances upon coordination with a metal ion [9, 10]. The classical coordination complex, cis-DDP or cisplatin (cis-diammine dichloroplatinum), has been the subject of much recent attention towards the metal-based chemotherapy, because of its beneficial effects in the treatment of cancer.…”
Section: Introductionmentioning
confidence: 99%